Characteristics of headaches attributed to SARS-CoV-2 vaccination and factors associated with its frequency and prolongation: a cross-sectional cohort study

BackgroundHeadache is the most frequent neurological adverse event following SARS-CoV-2 vaccines. We investigated the frequency, characteristics, and factors associated with post-vaccination headaches, including their occurrence and prolongation (& GE; 48 h). MethodsIn this observational cross-sectional cohort study, retrospective data collected between April 2021-March 2022 were analyzed. Univariate and multivariate logistic regressions were used to evaluate the effect of clinicodemographic factors on the odds of post-vaccination headache occurrence and prolongation. ResultsOf 2,500 people who were randomly sent the questionnaire, 1822 (mean age: 34.49 & PLUSMN; 11.09, female: 71.5%) were included. Headache prevalence following the first (V-1), second (V-2), and third (V-3) dose was 36.5, 23.3, and 21.7%, respectively (p < 0.001). Post-vaccination headaches were mainly tension-type (46.5%), followed by migraine-like (36.1%). Headaches were mainly bilateral (69.7%), pressing (54.3%), moderate (51.0%), and analgesic-responsive (63.0%). They mainly initiated 10 h [4.0, 24.0] after vaccination and lasted 24 h [4.0, 48.0]. After adjusting for age and sex, primary headaches (V-1: aOR: 1.32 [95%CI: 1.08, 1.62], V-2: 1.64 [1.15, 2.35]), post-COVID-19 headaches (V-2: 2.02 [1.26, 3.31], V-3: 2.83 [1.17, 7.47]), headaches following the previous dose (V-1 for V-2: 30.52 [19.29, 50.15], V-1 for V-3: 3.78 [1.80, 7.96], V-2 for V-3: 12.41 [4.73, 35.88]), vector vaccines (V-1: 3.88 [3.07, 4.92], V-2: 2.44 [1.70, 3.52], V-3: 4.34 [1.78, 12.29]), and post-vaccination fever (V-1: 4.72 [3.79, 5.90], V-2: 6.85 [4.68, 10.10], V-3: 9.74 [4.56, 22.10]) increased the odds of post-vaccination headaches. Furthermore, while primary headaches (V-1: 0.63 [0.44, 0.90]) and post-COVID-19 headaches (V-1: 0.01 [0.00, 0.05]) reduced the odds of prolonged post-vaccination headaches, psychiatric disorders (V-1: 2.58 [1.05, 6.45]), headaches lasting & GE;48 h following the previous dose (V-1 for V-2: 3.10 [1.08, 10.31]), and migraine-like headaches at the same dose (V-3: 5.39 [1.15, 32.47]) increased this odds. ConclusionPatients with primary headaches, post-COVID-19 headaches, or headaches following the previous dose, as well as vector-vaccine receivers and those with post-vaccination fever, were at increased risk of post-SARS-CoV-2-vaccination headaches. Primary headaches and post-COVID-19 headaches reduced the odds of prolonged post-vaccination headaches. However, longer-lasting headaches following the previous dose, migraine-like headaches at the same dose, and psychiatric disorders increased this odd.